Back

Decreased risk of cardiovascular events in patients with atrial fibrillation treated with lipid-lowering therapy: 2-year follow-up of the Global ETNA-AF program

30 August 2025 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Antiarrhythmic and upstream pharmacological therapy in atrial fibrillation Stroke in Atrial Fibrillation ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Joris R De Groot

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

6 More presentations in this session

Presentation thumbnail
Use of class ic antiarrhythmic drugs in atrial fibrillation with structural heart disease: a nationwide cohort study
Assistant Professor J. Jeong (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
A multicenter analysis of atrial fibrillation burden reduction with antiarrhythmic drugs in patients with cardiac implantable electronic devices
Doctor S. Schwartz (New York, US)
Abstract Slides Video
Presentation thumbnail
Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomised controlled trials
Doctor M. Casuso Alvarez (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Improving management of patients with atrial fibrillation in the emergency department based on an aggressive rhythm control strategy. The HEROMEDICUS study.
Doctor N. Argyriou (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Impact of statin and ezetimibe for the prevention of stroke in patients with atrial fibrillation
Associate Professor K. Lee (Gwangju, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Antiarrhythmic and upstream pharmacological therapy in atrial fibrillation

The Event

Event poster

ESC Congress 2025

30 August 2025 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Statin therapy and synergistic effect of ezetimibe for the prevention of stroke with atrial fibrillation populations: nationwide cohort study
thumbnail
Congress Presentation
AF patients in routine practice: a long-term perspective from ETNA-AF-Europe
thumbnail
Congress Presentation
Low rates of haemorrhagic stroke, not increased by age, renal/hepatic impairment, concomitant anti-platelet use and high CHA2DS2-VASc scores, in the 4-year follow-up of ETNA-AF-Europe

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources